Who Is A Bigger Threat - Doctors Or Lawyers

[Psycho]

Who Is A Bigger Threat - Doctors Or Lawyers

 

The DC City Council has the power to regulate most industry, products and services offered but they allow dangerous things to take place because they have been bribed.

 

Chemotherapy is basically ineffective in the vast majority of cases in which it is given.

 

Chemotherapy is ineffective in treating most cancers, the exceptions being acute lymphocytic leukemia, Hodgkin's disease, nonseminomatous testicular cancer, as well as a few very rare forms of cancer, including choriocarcinoma, Wilm's tumor, and retinoblastoma.

 

Ralph Moss, PhD, former Director of Information for Sloan Kettering Cancer Research Center

 

 

...as a chemist trained to interpret data, it is incomprehensible to me that physicians can ignore the clear evidence that chemotherapy does much, much more harm than good.

 

Alan C Nixon, PhD, former president of the American Chemical Society

 

 

Except for two forms of cancer, chemotherapy does not cure. It tortures and may shorten life -- no one can tell from the available data.

 

Dr. Candace Pert, Georgetown University School of Medicine

 

 

How can that be true of the main cancer treatment in the U.S.? Fact is, no solid scientific studies or clinical trials prove chemotherapy's effectiveness, except in a small percentage of very rare types of cancer. For solid tumors of adults, the vast majority of cancer, or anything that has metastasized, chemotherapy just doesn't work.

 

A German epidemiologist from the Heidelberg/Mannheim Tumor Clinic, Dr. Ulrich Abel has done a comprehensive review and analysis of every major study and clinical trial of chemotherapy ever done. His conclusions should be read by anyone who is about to embark on the Chemo Express. To make sure he had reviewed everything ever published on chemotherapy, Abel sent letters to over 350 medical centers around the world asking them to send him anything they had published on the subject. Abel researched thousands of articles: it is unlikely that anyone in the world knows more about chemotherapy than he.

 

The analysis took him several years, but the results are astounding: Abel found that the overall worldwide success rate of chemotherapy was "appalling" because there was simply no scientific evidence available anywhere that chemotherapy can "extend in any appreciable way the lives of patients suffering from the most common organic cancers." Abel emphasizes that chemotherapy rarely can improve the quality of life. He describes chemotherapy as "a scientific wasteland" and states that at least 80 percent of chemotherapy administered throughout the world is worthless, and is akin to the "emperor's new clothes" - neither doctor nor patient is willing to give up on chemotherapy even though there is no scientific evidence that it works.

 

When any chemotherapeutic drug is spilled in the hospital or anywhere en route, it is classified as a major biohazard. Yet this same agent is going to be put into the human body and is expected to cure it of disease? What's wrong with this picture?

 

...and since a picture says more than a thousand words, here is a reduced-size rendering of the burning and scarring resulting of chemotherapy fluid spilling onto the unprotected hand. Does this picture make one feel safer to have such an extremely aggressive toxic chemical administered within one's body via intravenous injection? Knowing that our outer skin is actually better protected against any impacts than our inner body? That is also why nurses administering chemotherapy have to wear protective gloves and follow the most stringent security measures in case of any accidental spills of chemotherapy beyond 5 cc, see High risks involved in accidental spillage of chemotherapy drugs. (Click on picture to see enlarged version.)

 

In evaluating a therapeutic regimen, the only thing that really matters is death rate - will a treatment significantly extend a patient's life. I'm not talking about life as a vegetable, but the natural healthy independent lifespan of a human being.

 

Media stories and most articles in medical journals go to great lengths to hide the underlying numbers of people dying from cancer, by talking about other issues. In Questioning Chemotherapy, Dr. Ralph Moss talks about several of the ways they do it:

 

Response rate is a favorite. If a dying patient's condition changes even for a week or a month, especially if the tumor shrinks temporarily, the patient is listed as having "responded to" chemotherapy. No joke! The fact that the tumor comes back stronger soon after chemo is stopped is not figured into the equation. The fact that the patient has to endure horrific side effects in order to temporarily shrink the tumor is not considered. That fact that the patient soon dies is not figured into the equation. The idea is to sell, sell, and sell.

 

Sell chemotherapy.

 

Also in the media we find the loud successes chemotherapy has had on certain rare types of cancer, like childhood leukemia, and Hodgkin's lymphoma. But for the vast majority of cancer cases, chemo is a bust. Worse yet, a toxic one.

 

Even with Hodgkins, one of chemo's much-trumpeted triumphs, the cure is frequently a success, but the patient dies. He just doesn't die of Hodgkin’s disease, that's all. In the 1994 Journal of the National Cancer Institute, they published a 47-year study of more than 10,000 patients with Hodgkin’s lymphoma, who were treated with chemotherapy. Even though there was success with the Hodgkin’s itself, these patients encountered an incidence of leukemia that was six times the normal rate. This is a very common type of reported success within the cancer industry - again, the life of the patient is not taken into account.

 

In evaluating any treatment, there must be a benefits/risks analysis. Due to gigantic economic pressures, such evaluation has been systematically put aside in the U.S. chemotherapy industry.

 

FDA drug approval: eye opening behind-the-scenes report on FDA advisers' industry ties.

 

More than half of the experts hired to advise the government on the safety and effectiveness of medicine have financial relationships with the pharmaceutical companies that will be helped or hurt by their decisions, a USA TODAY study found...The experts are supposed to be independent, but ... 54% of the time, they have a direct financial interest in the drug or topic they are asked to evaluate...Federal law generally prohibits the FDA from using experts with financial conflicts of interest, but the FDA has waived the restriction more than 800 times since 1998...The expert panel's "consumer representative," whose assignment is to defend consumers' interests, had the most extensive financial relationship with Johnson & Johnson.

 

In recent years, the FDA has followed every advisory committee recommendation to approve or reject a medicine - except once... The federal agency is forbidden from using experts with financial conflicts unless a waiver is granted, usually on the grounds that the experts' value outweighs the seriousness of the conflict. The FDA grants these waivers routinely... Many financial conflicts are considered too small to require disclosure or a waiver and were not counted in USA Today’s study. For example, a committee member can be paid up to $50,000 a year by a drug company without any financial conflict being disclosed if the work was on a topic other than what the committee is evaluating... Financial conflicts are so common that eight of 10 members who evaluated the drug Aggrastat, made by Merck, had conflicts of interest...

 

 

Dennis Cauchon in USA TODAY